Tatiana Prowell
#163,266
Most Influential Person Now
American medical oncologist specializing in breast cancer
Tatiana Prowell's AcademicInfluence.com Rankings
Tatiana Prowellphilosophy Degrees
Philosophy
#12905
World Rank
#18060
Historical Rank
#2562
USA Rank
Logic
#9924
World Rank
#12661
Historical Rank
#1829
USA Rank

Download Badge
Philosophy
Why Is Tatiana Prowell Influential?
(Suggest an Edit or Addition)According to Wikipedia, Tatiana Michelle Prowell is an American medical oncologist specializing in breast cancer. She is an Associate Professor of Oncology at Johns Hopkins School of Medicine and Breast Cancer Scientific Liaison at the U.S. Food & Drug Administration.
Tatiana Prowell's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) (2895)
- Pathological complete response and accelerated drug approval in early breast cancer. (2012) (315)
- Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. (2017) (274)
- FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. (2010) (207)
- CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. (2019) (143)
- Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer (2018) (109)
- Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (99)
- Seamless Oncology-Drug Development. (2016) (91)
- Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group. (2017) (80)
- A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer (2012) (58)
- What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? (2004) (44)
- FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer (2020) (43)
- Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology (2018) (42)
- Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (42)
- Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis. (2019) (33)
- Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond. (2006) (31)
- Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole (2011) (28)
- Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. (2021) (26)
- Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials (2015) (26)
- Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast Cancer. (2019) (23)
- Lipophilic statins merit additional study for breast cancer chemoprevention. (2006) (17)
- U.S. FDA Drug Approvals for Breast Cancer - A Decade in Review. (2021) (11)
- Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play? (2006) (10)
- Benefit of CDK 4/6 inhibition in less common breast cancer subsets: A U.S. Food and Drug Administration pooled analysis. (2018) (9)
- Fatal neutropenic enterocolitis associated with docetaxel use: A review of cases reported to the United States Food and Drug Administration Adverse Event Reporting System (2020) (7)
- Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop (2021) (6)
- No Decision Is Final: Career Planning and Career Transitions. (2018) (4)
- U.S. FDA Drug Approvals for Gynecological Malignancies - A Decade in Review. (2021) (3)
- Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy - Authors' reply. (2020) (3)
- Postmarketing Colitis Cases Associated With Alpelisib Use Reported to the US Food and Drug Administration. (2022) (2)
- Extended adjuvant therapy for breast cancer--how much is enough? (2007) (1)
- A prospective study of adjuvant anastrozole and gene promoter methylation in the contralateral breast of high-risk women (2008) (1)
- A short-term biomarker modulation prevention study of simvastatin in women at increased risk for breast cancer. (2010) (1)
- Words Matter: Use of Respectful Language in Oncology (2021) (1)
- Abstract P5-14-02: Time to treatment discontinuation as a pragmatic endpoint: A U.S. Food and Drug Administration pooled analysis of CDK 4/6 inhibitors (2019) (1)
- Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years (2018) (0)
- Abstract P5-17-01: A definition of a high-risk early-breast cancer population based on data from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) meta-analysis (2013) (0)
- Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer. (2021) (0)
- Quality of life (QOL) changes in breast cancer patients participating in an anastrozole secondary prevention trial (2008) (0)
- Metastatic Breast Cancer: Tailored Endocrine Therapy for Premenopausal Women (2006) (0)
- Potential of Neoadjuvant Trials to Support Drug Approval in High-Risk Early Breast Cancer (2014) (0)
- Overall Survival in Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer Treated with a CDK 4/6 Inhibitor Plus Fulvestrant: A U.S. Food and Drug Administration Pooled Analysis (2021) (0)
- Disease-free survival was greater with letrozole than tamoxifen in postmenopausal women with early breast cancer. (2006) (0)
- Oncology Drug Development: A Regulatory Perspective (2016) (0)
- Overall survival in patients with breast cancer treated with a CDK 4/6 inhibitor plus fulvestrant: A U.S. Food and Drug Administration pooled analysis. (2021) (0)
This paper list is powered by the following services:
Other Resources About Tatiana Prowell
What Schools Are Affiliated With Tatiana Prowell?
Tatiana Prowell is affiliated with the following schools: